Bordetella pertussis fimbriae 2/3 antigen Completed Phase 4 Trials for Diphtheria / Tetanus / Pertussis Prevention

CompletedPrevention4 IdentifierTitleDrugs
NCT01137435Post Marketing Surveillance for ADACEL™ in South Korea
NCT00319553Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
NCT00347958Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
NCT00457249A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
NCT00712959Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
NCT01311557Study of Adacel® Vaccine Administered to Persons 10 Years of Age
NCT01711645Tdap Vaccine in Post-Partum Women